CBU
PTGX icon

CIBC Bancorp USA’s Protagonist Therapeutics PTGX Stock Holding History

CIBC Bancorp USA’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$635K Buy
5,180
+2,212
+75% +$231K ﹤0.01% 1225
2026
Q1 		$313K Buy
+2,968
New +$263K ﹤0.01% 1399
2025
Q3 		$412K Buy
+6,205
New +$353K ﹤0.01% 942

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

CIBC Bancorp USA's PTGX Position: Q2 2026 in Review

CIBC Bancorp USA increased its Protagonist Therapeutics (PTGX) stake by 75% in Q2 2026, buying an estimated $231K and bringing the position to 5,180 shares worth $635K. The position accounts for ﹤0.01% of the portfolio, ranked #1225.

CIBC Bancorp USA first reported a position in PTGX in Q3 2025 and has held it in 3 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • CIBC Bancorp USA held 5,180 shares of Protagonist Therapeutics worth $635K as of Q2 2026.
  • CIBC Bancorp USA bought 2,212 Protagonist Therapeutics shares in Q2 2026, an estimated $231K.
  • Protagonist Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1225 holding.
  • CIBC Bancorp USA first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.